Matrix Metalloproteinases and Microhemorrhages in Alzheimer's Immunotherapy
Author Information
Author(s): Donna M. Wilcock, Dave Morgan, Marcia N. Gordon, Tiffany L. Taylor, Lisa A. Ridnour, David A. Wink, Carol A. Colton
Primary Institution: University of Kentucky Sanders-Brown Center on Aging
Hypothesis
The study investigates the activation of matrix metalloproteinases (MMPs) following anti-Aβ immunotherapy and its implications for microhemorrhage occurrence.
Conclusion
Increased activity of the MMP system is likely a major factor in the occurrence of microhemorrhages associated with anti-Aβ immunotherapy.
Supporting Evidence
- MMP2 and MMP9 systems were activated by anti-Aβ immunotherapy.
- A significant increase in microhemorrhages was observed in treated mice.
- The study utilized both active vaccination and passive immunization methods.
Takeaway
This study found that treatments for Alzheimer's disease can cause certain proteins to become more active, which might lead to small bleeding in the brain.
Methodology
The study examined MMP activity in transgenic mice receiving either active vaccination or passive immunization against Aβ.
Limitations
The study was conducted in mouse models, which may not fully replicate human responses.
Participant Demographics
Transgenic mice aged 12 to 22 months were used in the study.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website